This activity is expired and is no longer available for CME credit.


Systemic Sclerosis With Pulmonary Involvement: Improving Diagnosis and Advances in Treatment

Author(s)/Faculty: Elana J. Bernstein, MD, MSc; Richard M. Silver, MD; Elizabeth R. Volkmann, MD, MS
Release Date: 3/17/2020Expiration Date: 3/16/2021
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Systemic sclerosis (SSc) is a disabling autoimmune disorder that can cause diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs. Affecting approximately 2 million people worldwide, SSc is challenging to diagnose due to its nonspecific symptomatology and rare nature. Up to 90% of patients with SSc will have pulmonary involvement, and the presence of interstitial lung disease (ILD) is associated with poor prognosis. Currently, no disease-modifying therapies are available for treating SSc-ILD, but several agents approved for idiopathic pulmonary fibrosis are in late-stage clinical development. In this recorded symposium, experts review the presentation and workup of SSc, while addressing the burden of disease as well as evaluating the clinical evidence for current and emerging treatment options. Faculty also address the impact of SSc-ILD on patient prognosis and emphasize the importance of multidisciplinary care for timely identification of patients who may benefit from new treatments.